…and ethical uses of psychedelic medicines (Belouin, Averill, Henningfield, et al., 2023; Also see Yaden, Griffiths & Potash, 2023; Yaden, Yaden & Griffiths, 2021). Read Dr. Henningfield’s full comment here….
Expertise In his far-reaching career, Jack’s research and contributions to drug regulation and public policy have contributed to the development of important medicines and other approaches for addressing addiction and…
June 11-15, 2022 | MINNEAPOLIS, MN Jack Henningfield, August Buchhalter, and Ryan Lanier will be attending CPDD. VIEW CONFERENCE WEBSITE…
June 17-21, 2023 | Denver, CO Judy Ashworth, Jack Henningfield, August Buchhalter, Ryan Lanier and Caitlyn Durgin will be attending. VIEW CONFERENCE WEBSITE Posters: Within-Subject Variations in Opioid Sensitivity Across…
September 27-28, 2023 | Rockville, MD Jack Henningfield, Judy Ashworth, and Ryan Lanier will be attending. VIEW CONFERENCE…
September 10-12, 2023 | Bellevue, WA Jack Henningfield will be attending and participating in a panel discussion. VIEW CONFERENCE Discussion: Symposium 6: The Tightrope of Substance Abuse Potential: The Preclinical…
Jack Henningfield, PhD, Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates Presented as part of the NIH Psilocybin Speaker Series, April 22-June 10, 2021 VISIT THE SPEAKER…
December 3-6, 2023 | Tampa, FL Jack Henningfield will be attending. VIEW CONFERENCE Posters:No Indication of Abuse or Withdrawal Potential with Esmethadone (REL-1017): Results From Two Phase 3 Randomized Placebo-Controlled…